Applying Clinical Pharmacology Learnings from Late-Stage CD3 Bispecific Programs to Optimize Early Autoimmune T-Cell Engager Development
- Evaluating how clinical pharmacology insights from advanced CD3 bispecific programs can inform first-in-human study design, dose escalation strategies, cytokine release syndrome mitigation, and therapeutic window optimization in autoimmune disease settings
- Integrating pharmacokinetic, pharmacodynamic, and biomarker-driven approaches to better predict immune-cell depletion, target engagement, and early efficacy signals, enabling more informed and efficient clinical development decisions
- Leveraging translational and early human data from late-stage T-cell engager programs to refine patient selection, dosing paradigms, and safety monitoring frameworks that support accelerated development and improved patient outcomes